CAP方案治疗原发性非小细胞型肺癌

CAP Regimen in the Treatment Primary Non-small Cell Lung Cancer(NSCLC)

摘要: 本文报导31例用CAP方案治疗的非小细胞性肺癌.Ⅱ期1例,Ⅲ期10例,Ⅳ期20例,总有效率为35.5%,其中CR1例,PR10例,NC10例,PD10例.中位生存期8个月,有效病例为17个月.本文对该方案的副反应,可行性等进行了分析.

Abstract: The paper reactted cyclophosphamide(CTX). doxorubicin(ADM). cisplatin(PDD) in the treatment primary 31 cases NSCLS. In the thirty first cases, Ⅰ of case was stage Ⅱ of the NSCLC, 10 of cases were stage Ⅲ B, 20 of cases were stage Ⅳ. Total response rate achieved 35.5%. One case achieved complete response(CR). In the thirty first cases, ten Of cases achieved partial response(PR), ten of cases were no change(NC), ten of cases were progress disease(PD).The median survival time was 8 months and in which of the response patients (CR+PR) was 17 months. The paper analysised CAP regimetn toaxicity.availability, and so.